Johnson & Johnson decided to kick start the new year by striking 15 new collaborations to drive the development of novel solutions to impact healthcare.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Thermo Fisher Scientific and Illumina have announced a commercial agreement that enables Illumina to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing platforms.
Alnylam Pharmaceuticals have announced a strategic restructuring of their RNAi therapeutics alliance with French pharmaceuticals company, Sanofi.
To kick off the JP Morgan Healthcare Conference, Edico Genome and Genomics England announced a new partnership to strengthen the accuracy and consistency of next-generation sequencing (NGS) data analysis in Genomics England’s Rare Disease Pilot.
Pfizer has announced that it will be abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease.
The first US Food and Drug Administration-approved gene therapy for an inherited disorder will cost you $425,000 per eye.
Biopharma, research- and healthcare facilities are getting more and more interested in genomics data. A fresh example is the $58 million financing round DNAnexus just completed.
GlaxoSmithKline Plc has received clearance by the UK for its most expensive treatment, for an illness known as “bubble-boy disease.”
Novartis has received U.S. Food and Drug Administration approval for its breakthrough therapy designation for treating some breast cancer patients.
The commissioner of the Food and Drug Administration questions whether the right financial incentives are in place for drugmakers who develop orphan drugs for rare diseases.
DNAnexus announce equity investment to support it’s continued expansion in the clinical trials market, as well as the deployment of its Translational Informatics Suite.
Roche has confirmed plans to buy US group Ignyta for $27 a share in a cash deal totaling around $1.7 billion, allowing themselves access to experimental cancer medicines.
MilliporeSigma has signed a commercial supply agreement with bluebird bio for viral vector manufacturing, in the hopes of accelerating treatments for serious diseases.